Zai Lab Stock Price, News & Analysis (NASDAQ:ZLAB) $27.50 +0.21 (+0.77%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$26.57▼$28.0350-Day Range$22.97▼$30.0152-Week Range$22.35▼$49.81Volume509,301 shsAverage Volume388,930 shsMarket Capitalization$2.72 billionP/E RatioN/ADividend YieldN/APrice Target$79.97 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Zai Lab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside190.8% Upside$79.97 Price TargetShort InterestBearish4.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 13 Articles This WeekInsider TradingAcquiring Shares$134,650 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.48) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector506th out of 953 stocksPharmaceutical Preparations Industry239th out of 448 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.97, Zai Lab has a forecasted upside of 190.8% from its current price of $27.50.Amount of Analyst CoverageZai Lab has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.10% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Zai Lab has recently increased by 7.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 2.5 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Zai Lab this week, compared to 3 articles on an average week.Search Interest2 people have searched for ZLAB on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have bought 3,134.45% more of their company's stock than they have sold. Specifically, they have bought $134,650.00 in company stock and sold $4,163.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions43.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($3.48) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -8.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -8.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zai Lab Stock (NASDAQ:ZLAB)Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.Read More ZLAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLAB Stock News HeadlinesDecember 2, 2023 | americanbankingnews.comFY2024 Earnings Forecast for Zai Lab Limited Issued By Leerink Partnrs (NASDAQ:ZLAB)December 1, 2023 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Price Target Raised to $66.00 at JPMorgan Chase & Co.December 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 1, 2023 | americanbankingnews.comZai Lab Limited (NASDAQ:ZLAB) Expected to Post Q1 2024 Earnings of ($0.74) Per ShareNovember 30, 2023 | markets.businessinsider.comAnalyst Ratings for Zai LabNovember 27, 2023 | msn.comZai Lab Limited - ADR (ZLAB) Price Target Increased by 9.31% to 32.49November 26, 2023 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Up 4.4%November 19, 2023 | seekingalpha.comZai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade)December 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 17, 2023 | msn.comZai Lab executive purchases 5,000 sharesNovember 17, 2023 | finance.yahoo.comInstitutional investors may adopt severe steps after Zai Lab Limited's (NASDAQ:ZLAB) latest 6.3% drop adds to a year lossesNovember 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Technology Stocks: Zai Lab (ZLAB), Navitas Semiconductor (NVTS)November 9, 2023 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | finanznachrichten.deZai Lab Limited: Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 7, 2023 | finance.yahoo.comZai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 7, 2023 | benzinga.comRecap: Zai Lab Q3 EarningsNovember 7, 2023 | finance.yahoo.comZai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 6, 2023 | uk.finance.yahoo.comZai Lab Ltd (1ZLB.SG)November 3, 2023 | msn.comZai Lab Limited - ADR (ZLAB) Price Target Increased by 5.97% to 29.72October 26, 2023 | markets.businessinsider.comGoldman Sachs Maintains Buy Rating for Zai Lab: Here's What You Need To KnowOctober 23, 2023 | finance.yahoo.comFurther weakness as Zai Lab (NASDAQ:ZLAB) drops 4.5% this week, taking three-year losses to 72%October 18, 2023 | finance.yahoo.comZai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023October 18, 2023 | markets.businessinsider.comStrong Drug Sales and Market Position Drive Buy Rating for Zai Lab: An In-depth AnalysisOctober 17, 2023 | benzinga.comThe Latest Analyst Ratings for Zai LabOctober 17, 2023 | finance.yahoo.comUltragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?September 18, 2023 | finance.yahoo.comZai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in ChinaSeptember 7, 2023 | seekingalpha.comZai Lab Stock: De-Risking Through Market TappingSee More Headlines Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,036Year FoundedN/APrice Target and Rating Average Stock Price Target$79.97 High Stock Price Target$128.00 Low Stock Price Target$62.50 Potential Upside/Downside+190.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-443,290,000.00 Net Margins-114.22% Pretax Margin-114.22% Return on Equity-31.19% Return on Assets-26.51% Debt Debt-to-Equity RatioN/A Current Ratio7.68 Quick Ratio7.33 Sales & Book Value Annual Sales$215.04 million Price / Sales12.64 Cash FlowN/A Price / Cash FlowN/A Book Value$8.91 per share Price / Book3.09Miscellaneous Outstanding Shares98,840,000Free Float93,670,000Market Cap$2.72 billion OptionableOptionable Beta1.06 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Ying Du Ph.D. (Age 57)Founder, Chairperson & CEO Comp: $1.67MMr. Joshua L. Smiley (Age 53)President & COO Comp: $647.11kDr. Rafael G. Amado M.D. (Age 59)President and Head of Global Oncology Research & Development Comp: $477kDr. Harald Reinhart M.D. (Age 71)President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases Comp: $923.33kDr. Yajing Chen Ph.D.Chief Financial OfficerDr. Peter Huang Ph.D.Chief Scientific OfficerMr. Frazor Titus Edmondson III (Age 57)J.D., Chief Legal Officer & Corporate Secretary Comp: $829kMs. Ann E. Beasley J.D.Chief Compliance OfficerDr. Ning Xu M.D. (Age 58)Executive VP & Head of Clinical Operations Dr. Jonathan J. Wang MBA (Age 41)Ph.D., Chief Business Officer More ExecutivesKey CompetitorsPrestige Consumer HealthcareNYSE:PBHMoonLake ImmunotherapeuticsNASDAQ:MLTXOrganon & Co.NYSE:OGNCorcept TherapeuticsNASDAQ:CORTAmphastar PharmaceuticalsNASDAQ:AMPHView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 152,724 shares on 12/1/2023Ownership: 1.945%Deutsche Bank AGSold 2,624 shares on 11/24/2023Ownership: 0.018%Polar Capital Holdings PlcSold 66,747 shares on 11/22/2023Ownership: 0.116%Joshua L SmileyBought 5,000 shares on 11/16/2023Total: $134,650.00 ($26.93/share)Alps Advisors Inc.Bought 2,263 shares on 11/15/2023Ownership: 0.074%View All Insider TransactionsView All Institutional Transactions ZLAB Stock Analysis - Frequently Asked Questions Should I buy or sell Zai Lab stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks. What is Zai Lab's stock price target for 2024? 4 analysts have issued 1 year target prices for Zai Lab's stock. Their ZLAB share price targets range from $62.50 to $128.00. On average, they anticipate the company's stock price to reach $79.97 in the next twelve months. This suggests a possible upside of 190.8% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts. How have ZLAB shares performed in 2023? Zai Lab's stock was trading at $30.70 at the start of the year. Since then, ZLAB shares have decreased by 10.4% and is now trading at $27.50. View the best growth stocks for 2023 here. When is Zai Lab's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our ZLAB earnings forecast. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $69.23 million for the quarter, compared to the consensus estimate of $67.12 million. Zai Lab had a negative trailing twelve-month return on equity of 31.19% and a negative net margin of 114.22%. What ETFs hold Zai Lab's stock? ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA), Fidelity Disruptive Medicine ETF (FMED) and Invesco Golden Dragon China ETF (PGJ) and What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN). When did Zai Lab IPO? (ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO. Who are Zai Lab's major shareholders? Zai Lab's stock is owned by many different institutional and retail investors. Top institutional investors include Invesco Ltd. (3.25%), Wellington Management Group LLP (1.95%), Segantii Capital Management Ltd (1.81%), Bamco Inc. NY (1.60%), FMR LLC (1.28%) and Rock Springs Capital Management LP (1.25%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Joshua L Smiley, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis, Yajing Chen and Ying Du. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ZLAB) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.